Pertuzumab และ Trastuzumab ในมะเร็งเต้านม HER2-Positive ระยะเริ่มเป็น

Scottish Medicines Consortium decisions For trastuzumab · SMC No 92813 Trastuzumab for the treatment of adult patients

Trastuzumab has also been shown to penetrate an impaired blood–brain barrier to a limited degree, such as during radiotherapy, and intrathecal delivery of

trastuzumab trastuzumab Early breast cancer Herceptin is indicated for the treatment of patients with HER2-positive early breast cancer: following surgery

trastuzumab Cardiotoxicity Trastuzumab is a monoclonal antibody tyrosine kinase inhibitor that targets the HER2 receptor often over overexpressed or overactive in breast